COVID-19 and Immunosuppressive Therapy in Ocular Inflammatory Disease, a Telemedicine Survey.
Ocul Immunol Inflamm
; 29(4): 734-740, 2021 May 19.
Article
in English
| MEDLINE | ID: covidwho-1334067
ABSTRACT
Purpose:
Determine the risk of immunomodulatory therapy (IMT) for COVID-19 infection morbidity.Method:
A telemedicine survey on patients of a referral uveitis clinic was performed. Signs of infection, habits, and hospitalizations during the 7 months of the COVID-19 pandemic prior to the study date were recorded. Suggestive findings in chest CT scan and/or positive RT-PCR were considered as confirmed COVID-19 infection while those with only suggestive symptoms were considered as suspected cases. Risk factors including sanitary measures and IMT were compared between patients with confirmed cases and patients without infection.Result:
694 patients were included. Eight patients were identified as confirmed cases and 22 patients as suspected cases of COVID-19 infection. Close contact with infected persons was the only significant risk factor for contracting COVID-19.Conclusion:
Using IMT did not affect hospitalization and/or ICU admission and can thus be continued during the pandemic, provided that instructions for preventive measures are followed.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Uveitis
/
Immunosuppression Therapy
/
Telemedicine
/
Immunomodulation
/
Pandemics
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Ocul Immunol Inflamm
Journal subject:
Allergy and Immunology
/
Ophthalmology
Year:
2021
Document Type:
Article
Affiliation country:
09273948.2021.1949477
Similar
MEDLINE
...
LILACS
LIS